Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veonetinib (AL8326) in ≥2nd Line SCLC, NSCLC and RCC
NCT05363280Phase 2Recruiting
- Sponsor
- Advenchen Laboratories
- Start
- Nov 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of AL8326 in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) (5 arms), sponsored by Advenchen Laboratories. Primary endpoints: Optimal biological dose at 12 months and Objective Response Rate at 24 months. Started Nov 2022; status: recruiting.
02
Drugs
AL8326
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05363280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363280.